All Posts Tagged With: "JNJ"
(MMM) 3M Company Beats Earnings Estimates
3M Company (MMM) announced first-quarter 2012 results before the market opened today, reporting earnings per share of $1.59, above the Zacks Consensus Estimate of $1.48 per share. Earnings per share surged...
(IART) Integra LifeScience Holdings Corporation Earns FDA Nod for Spine Device
Global provider of surgical implants and medical instruments, Integra LifeScience Holdings Corporation (IART) recently received the 510(k) clearance from the US Food and Drug Administration...
(MMM) Aerocraft Solution from 3M
3M Aerospace, part of 3M Company (MMM), meets the problem of substructure erosion in aircraft areas, like lavatories, galleys and doorways, which are frequently exposed to moisture through introduction of...
(C) The Thick of Q1 Earnings Season – Earnings Preview
We are jumping right into the thick of the first quarter reporting cycle this week, with more than 250 companies coming out with results, including 89 companies from the S&P 500.
We will have representation from the who’s who of the corporate world, with a number...
(JNJ) Healthcare Reform: Bad News for Big Pharma?
Healthcare reform could be a minefield for Big Pharma in the long run.
The Patient Protection and Affordable Care Act – less fondly known as “Obamacare” – was the big story to close out the month of March, as the Supreme Court officially took the case.
In...
(FRX) Forest Laboratories and Janssen Pharmaceutica Sue Generic Players
Forest Laboratories, Inc. (FRX) and Janssen Pharmaceutica NV, a Johnson & Johnson (JNJ) company, recently filed a joint lawsuit against...
(MDT) MedTech Industry Stock Outlook – March 2012 – Zacks Analyst Interviews
Last year proved to be challenging for medical technology (“MedTech”) stocks given the exigent economic conditions and the precarious healthcare environment. The performance of incumbent players was hamstrung by several macro issues, including sustained price and procedure...
(MDT) MedTech Industry Stock Outlook – March 2012 – Industry Outlook
Last year proved to be challenging for medical technology (“MedTech”) stocks given the exigent economic conditions and the precarious healthcare environment. The performance of incumbent players was hamstrung by several macro issues, including sustained price and procedure...
(DNDN) Dendreon’s Provenge Showing Bleak Outlook
Dendreon Corporation (DNDN) reported fourth-quarter 2011 earnings (including stock-based compensation expense but excluding other special items) of 37 cents per share, in contrast to the Zacks Consensus Estimate...
(PRGO) Perrigo Analyst Maintains Neutral Share rating
We have maintained our Neutral rating on Perrigo Company (PRGO) with a target price of $100.00 following appraisal of second quarter of fiscal 2012 results.
Perrigo reported second quarter EPS of $1.20,...
(GB) Greatbatch Buying NeuroNexus
Medical technology company Greatbatch (GB) is acquiring Michigan-based implantable medical device design firm NeuroNexus Technologies for roughly $12 million. The deal includes assumption of debt and future...
(MS) Facebook IPO: No Where to Go But Down?
Unless you’ve been living under a rock for the...
(SHPGY) Shire and Sangamo BioSciences Cut a Deal
Shire plc (SHPGY) and Sangamo BioSciences, Inc. (SGMO) recently entered into a collaboration and license agreement for the development...
(JNJ) Johnson & Johnson Earnings Scorecard
Following the release of fourth quarter and full year 2011 results, most of the analysts covering Johnson & Johnson (JNJ) have reduced their earnings estimates for 2012 and 2013. The revisions in estimates...
(PG) Procter & Gamble Results Come Up Short on Charges
Procter & Gamble Co.(PG) reported modest results for the second quarter 2012, with net earnings from continuing operations sliding 49.0% year over year to 57 cents a share, which missed the Zacks Consensus...
(EU) Stock Market News for January 25, 2012 – Market News
In yet another calm trading session, markets were pulled slightly lower after Eurozone ministers rejected a bond swap offer from Greece’s private creditors. While the Dow dropped lower and the S&P 500 reversed its five-day winning streak, Nasdaq added meager points after...
(JNJ) Mixed Earnings, Greece May Slip Markets
With nothing major on the domestic economic calendar, headlines about Greece’s as-yet unsuccessful negotiations with its bondholders to restructure its private debt may get some traction. But today’s market action will be mostly about the slew of mixed earnings reports...
(JNJ) Jan 24: Day of Earnings! – Economic Highlights
With nothing major on the domestic economic calendar, headlines about Greece’s as-yet unsuccessful negotiations with its bondholders to restructure its private debt may get some traction. But today’s market action will be mostly about the slew of mixed earnings reports...
(BMY) Bristol-Myers Squibb Company Kicks Off 2012 Pharma Deals
The spate of acquisitions in the pharma industry continues in 2012 with Bristol-Myers Squibb Company (BMY) announcing the first major deal of the new year. Major merger and acquisition (M&A) deals have...
(JNJ) Pharma & Biotech Stock Review & Outlook – Industry Outlook
With 2011 coming to an end, the pharmaceutical industry continues to face challenges like sluggish prescription trends, EU pricing pressure, intensifying generic competition, pipeline failures and limited late-stage catalysts. The next five years are expected to reflect a...
(JNJ) Spotlight on Hepatitis-C Market
Is the hepatitis-C market the next Mecca for the pharma/biotech sector? It seems so if we go by the flurry of activity and heightened interest in this market in the past few quarters. The hepatitis-C virus (HCV) market seems to have caught the eye of several pharma/biotech...
(GILD) Gilead’s Eviplera Drug is Cleared by European Medicines Agency
Gilead Sciences, Inc (GILD), the world’s largest HIV drug maker, received marketing authorization from the European Medicines Agency (EMA) for the single tablet regimen (STR), Eviplera, for the treatment...
(CRDC) Cardica Reaches Second Milestone for Their Microcutter
Surgical devices maker Cardica (CRDC) has achieved the second milestone for its Microcutter product line under its distribution pact with Century Medical, a leading supplier of medical equipment in Japan....
(MMM) 3M Company Analyst Reiterates Shares at Neutral
We recently maintained a Neutral recommendation on3M Company (MMM).
Based in St. Paul, Minnesota, 3M is a diversified technology company with manufacturing operations spread over 60 countries worldwide....
(JNJ) Bayer Cut to Underperform
We recently downgraded Bayer (BAYRY) to Underperform from Neutral purely on valuation grounds. We believe that the stock is overvalued at current levels.
Even though the US Food and Drug Administration (FDA) cleared Bayer/ Johnson & Johnson’s...
(MMM) 3M Company 2011 Third Quarter Earnings Scorecard
3M Company (MMM) reported modest results for the third quarter of 2011. The company achieved year-over-year top-line growth of 9.6%, as five out of six segments saw revenue growth. The bottom-line slipped...
(MDT) Medical Technology Industry Stock Outlook – November 2011 – Industry Outlook
The performance of incumbent players in the MedTech industry continued to be hamstrung by a spate of macro issues (including sustained price and procedure volume pressures) in the September quarter. The prevailing macroeconomic factors, pricing headwinds, austerity measures,...
(SYK) Stryker Third Quarter 2011 Earnings Scorecard
Orthopedic devices giant Stryker Corporation’s (SYK) third-quarter 2011 adjusted (excluding acquisition charges) earnings per share of 91 cents topped the Zacks Consensus Estimate of 89 cents and the year-ago...
(JNJ) Johnson & Johnson 2011 Third Quarter Earnings Scorecard
Following the release of third quarter 2011 results, majority of the analysts covering Johnson & Johnson (JNJ) revised their earnings estimates. While 2011 estimates have been revised in both directions,...
(GB) Greatbatch Analyst Raises Shares to Outperform
We upgrade our recommendation on Greatbatch (GB) to Outperform following its impressive third-quarter 2011 results. Adjusted earnings of 41 cents for the quarter outstripped the Zacks Consensus Estimate of...